PointState Capital’s Alder Biopharmaceuticals ALDR Stock Holding History

PointState Capital’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-150,000	Closed	-$7.95M	–	158
2015 Q2	$7.95M	Buy	+150,000	New	+$5.46M	0.09%	95
2015 Q1	–	Sell	-175,000	Closed	-$5.09M	–	155
2014 Q4	$5.09M	Sell	175,000 -200,000	-53%	-$3.59M	0.09%	91
2014 Q3	$4.75M	Buy	375,000 +100,000	+36%	+$1.51M	0.09%	73
2014 Q2	$5.52M	Buy	+275,000	New	+$3.87M	0.07%	94

Other funds holding ALDR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

PointState Capital's ALDR Position: Q3 2015 in Review

PointState Capital sold out of Alder Biopharmaceuticals (ALDR) in Q3 2015, closing a stake of 150,000 shares — an estimated $7.95M sold.

PointState Capital first reported a position in ALDR in Q2 2014 and held it in 4 quarters. The position peaked at $7.95M in Q2 2015. 140 funds tracked by Wall St. Rank hold ALDR as of Q3 2015.

PointState Capital reported no remaining Alder Biopharmaceuticals position as of Q3 2015 after selling out during the quarter.
PointState Capital sold 150,000 Alder Biopharmaceuticals shares in Q3 2015, an estimated $7.95M.
PointState Capital first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 4 quarters.
PointState Capital's Alder Biopharmaceuticals position peaked at $7.95M in Q2 2015.
140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2015.

Based on PointState Capital's 13F filing for Q3 2015, filed 16 Nov 2015.